

INFORME DE BÚSQUEDA DE PATENTES

N° de solicitud: NC2018/0012575

CRITERIOS PARA LA BÚSQUEDA (anexar pantallazo o reporte en PDF, junto con los boléanos utilizados**)

Palabras clave utilizadas		BROMODOMAIN INHIBITORS; CANCER; PIRIDIN; PIRIDAZIN; PIRIMIDIN.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 31/472, A61K 31/506, A61K 31/501, A61K 31/497, A61P 35/00.		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor*	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (con indicación, si procede, de las partes relevantes)	Categoría especial s de los document os citados**
ESPACENET, USPTO, ORBIT Y EPOQUENET	US2007213323	13/Septiembre/2007	2 a 40 y 44 - NIVEL INVENTIVO	Y
	US2010256698	07/Octubre/2010	No relevante	A
	US2012208814	16/Agosto/2012	1 - NOVEDAD	Y

** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.	“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.
---	--

Literatura no patente *Se incluye entre otros, toda la referencia de la literatura no patente.	-
Fecha del reporte de búsqueda:	09-02-2018

ESPACENET

Documents cited:	Search	[A]* EP1484320 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [A] 1-18 * page 2, paragraph [0001];; examples 146, 147, 305,306,311,3§16,318,323-326 *;
		[A]* WO2013027168 (PFIZER [US], et al) [A] 1-18 * page 1, 2nd paragraph;; example -; claim - *
International search		[X]* US2007213323 (IMOAI HASSAN J [CH], et al);
		[Y]* US2012208814 (DEMONT EMMANUEL HUBERT [GB], et al);
		[Y]* US2010256698 (TROTTER B WESLEY [US], et al)

ORBIT

Erase all Save entire strategy Create a script Export					
Menu Explorer << Patent family searches (FamPat)					
Searches Easy search Advanced search Semantic search Assignee search	Search Step	Result(s)	Query	Assistant	Source
	4	17	1 AND 2	Search history	FAMPAT
	3	5	PIRIDIN+1 AND 2	Search history	FAMPAT
	2	9850	PIRIDIN+	Search history	FAMPAT
	1	409	(HISTONE AND ACETYLATION) AND BROMODOMAINS/TXBI/SA/KEYWIN/PA	Easy search	FAMPAT
				Action	
				Show results Modify Save Alert Delete	
				Show results Modify Save Alert Delete	
				Show results Modify Save Alert Delete	
				Show results Modify Save Alert Delete	

USPTO

uspto

Patents Trademarks Fees and payment Help MyUSPTO

Public Patent Application Information Retrieval

Patent eBusiness

Patent Application Information Retrieval

Global DossierOrder Certified Application As FiledOrder Certified File WrapperView Order List

14/658,048BROMODOMAIN INHIBITORS87386.0010\US1

Select New CaseApplication DataTransaction HistoryImage File WrapperPatent Term AdjustmentsContinuity DataFeesPublished DocumentsAddress & Attorney/AgentAssignmentsDisplay References

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Patent Information

Patent Guidance and General Info

Codes, Rules & Manuals

Employee & Office Directories

Resources & Public Notices

Patent Searches

Patent Official Gazette

Search Patents & Applications

Search Biological Sequences

Copies, Products & Services

Other

Copyrights

Trademarks

Policy & Law

Reports

Mail Room Date	Document Code	Document Description	Document Category	Page Count	PDF
04-05-2016	N570	Communication - Re: Power of Attorney (PTOL-308)	PROSECUTION	1	☐
04-05-2016	N570	Communication - Re: Power of Attorney (PTOL-308)	PROSECUTION	1	☐
03-30-2016	PA..	Power of Attorney	PROSECUTION	2	☐
03-30-2016	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
08-05-2015	ISSUE.NTF	Issue Notification	PROSECUTION	1	☐
07-02-2015	NTC.PUB	Notice of Publication	PROSECUTION	1	☐
07-01-2015	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1	☐
07-01-2015	WFEE	Fee Worksheet (SB06)	PROSECUTION	2	☐
07-01-2015	N417	EFS Acknowledgment Receipt	PROSECUTION	2	☐
04-14-2015	OA.POSTCARD	A courtesy postcard sent by USPTO to users who opt-in for e-Office Action	PROSECUTION	1	☐
04-10-2015	M327	Miscellaneous Communication to Applicant - No Action Count	PROSECUTION	1	☐
04-06-2015	NOA	Notice of Allowance and Fees Due (PTOL-85)	PROSECUTION	10	☐
04-06-2015	INTV.SUM.EX	Examiner initiated interview summary (PTOL-413B)	PROSECUTION	1	☐

EPOQUENET



New connection on: : 10-12-2018 : 17:38:02 - Last disconnection on: : 07-12-2018 : 19:33:22

V 4.0.0.44803(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201820)) (RPM D201820)

Welcome to EPOQUE Rebuild under the Production Environment

[No database/cluster active] ..FI EPODOC

Database: EPODOC

Records: 111.763.625
Terms: 1.480.089.109
Occurrences: 22.642.774.196
Last Update: 20181209

[EPODOC: SS 1] BROMODOMAIN and INHIBITORS

Results in EPODOC **721**

[SS 2] piridin AND cancer

Results in EPODOC **1**

[SS 3] cancer

Results in EPODOC **221.716**

[SS 4] 3 and 1

Results in EPODOC **180**

[SS 5] 4 and piridin

Results in EPODOC **0**

[SS 6] 4

Results in EPODOC **180**

[SS 7] 6 and pirimidin

Results in EPODOC **0**

[SS 8] 6 and piridazin

Results in EPODOC **0**

[SS 9] 6 and piri+

Results in EPODOC **0**

[SS 10] 6

Results in EPODOC **180**

[SS 11] BRD

Results in EPODOC **174**

[SS 12] 10 AND 11

Results in EPODOC **0**

[SS 13] 6 and (brd)

Results in EPODOC **0**

[SS 14] 2

Results in EPODOC **1**

[SS 15] ..li ti ab pn

TI - SELECTIVE ANTAGONISTS OF EP4
RECEPTOR FOR **CANCER** TREATMENT

AB - FIELD: medicine,
pharmaceutics.SUBSTANCE: invention
relates to chemical and pharmaceutical
industry and represents application of
compound, selected from group, including
3-[2-(4-{2-ethyl-4,6-dimethyl-1H-
imidazo[4,5-c]**piridin**-1-yl}phenyl)ethyl)-1-
[(4-methylebenzene)sulphonyl]urea; 4-
((1S)-1-{{5-chloro-2-(4-fluorophenoxy)
benzoyl}amino}ethyl)-benzoic acid and 4-
[(1S)-1-{{5-chloro-2-(3-
fluorophenoxy)**piridin**-3-yl}carbonyl}
amino}ethyl]benzoic acid, or its
pharmaceutically acceptable salt for
production of medication for production
of **cancer** dimensions, associated with
prostaglandin E2 (PGE2) (for instance,
gastroenterologic **cancer**, prostate **cancer**,
lung **cancer** and breast **cancer**) in humans
or animals.EFFECT: obtaining
pharmaceutically acceptable salt for
production of medication for reduction
of **cancer** dimensions.5 cl, 5 dwg, 9 ex

PN - [RU2563817](#) C2 20150920

[SS 15]